Management of relapsed diffuse large B-cell lymphoma

Current Oncology Reports

Volumn 10, Issue 5, 2008, Pages 393-403

  Kenkre, Vaishalee Padgaonkar ^a   Smith, Sonali M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; PLATINUM COMPLEX; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

ADJUVANT THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; LARGE CELL LYMPHOMA; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; AGED; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ONCOLOGY; RADIOIMMUNOTHERAPY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 55749099667     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0061-4     Document Type: Review

References (74)

1. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346: 235-242.
2. Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23: 4117-4126.
3. Habermann TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24: 3121-3127.
4. Pfreundschuh M, Kloess M, Zeynalava E, et al.: Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood 2006, 108: Abstract 205.
5. Pfreundschuh M, Trumper L, Osterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7: 379-391.
6. Coiffier B, Feugier P, Mounier N, et al.: Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients [ASCO abstract]. J Clin Oncol 2007, 25(18S): 8009.
7. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329: 987-994.
8. Sehn LH, Berry B, Chhanabhai M, et al.: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109: 1857-1861.
9. Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333: 1540-1545.
10. Cheson BD, Pfistner B, Juweid ME, et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25: 579-586.
11. Shipp MA, Abeloff MD, Antman KH, et al.: International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. J Clin Oncol 1999, 17: 423-429.
12. Vose JM, Rizzo DJ, Tao-Wu J, et al.: Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 2004, 10: 116-127.
13. Josting A, Sieniawski M, Glossmann JP, et al.: High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 2005, 16: 1359-1365.
14. Blay J, Gomez F, Sebban C, et al.: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the Parma trial. Parma Group. Blood 1998, 92: 3562-3568.
15. Hamlin PA, Zelenetz AD, Kewalramani T, et al.: Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003, 102: 1989-1996.
16. Costa LJ, Micallef IN, Inwards DJ, et al.: Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL under-going autologous stem cell transplantation. Bone Marrow Transplant 2008, 41: 715-720.
17. Moskowitz CH, Bertino JR, Glassman JR, et al.: Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999, 17: 3776-3785.
18. Schot BW, Zijlstra JM, Sluiter WJ, et al.: Early FDGPET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007, 109: 486-491.
19. Spaepen K, Stroobants S, Dupont P, et al.: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13: 1356-1363.
20. Svoboda J, Andreadis C, Elstrom R, et al.: Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006, 38: 211-216.
21. Crocchiolo R, Canevari C, Assanelli A, et al.: Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008, 49: 727-733.
22. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403: 503-511.
23. Moskowitz CH, Zelenetz AD, Kewalramani T, et al.: Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005, 106: 3383-3385.
24. Kewalramani T, Zelenetz AD, Hedrick EE, et al.: High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis. Blood 2000, 96: 2399-2404.
25. Vose JM, Zhang MJ, Rowlings PA, et al.: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001, 19: 406-413.
26. Rodriguez J, Caballero MD, Gutierrez A, et al.: Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience. Ann Oncol 2004, 15: 1504-1509.
27. Corazzelli G, Russo F, Capobianco G, et al.: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/ mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study. Ann Oncol 2006, 17(Suppl 4): Iv18-iv24.
28. van Besien K, Rodriguez A, Tomany S, et al.: Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 2001, 27: 397-404.
29. Vellenga E, van Putten WL, van't Veer MB, et al.: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood 2008, 111: 537-543.
30. Kewalramani T, Zelenetz AD, Nimer SD, et al.: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103: 3684-3688.
31. Sieniawski M, Staak O, Glossmann JP, et al.: Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007, 86: 107-115.
32. Fenske TS, Parameswaran H, Carreras J, et al.: Pretransplant rituximab therapy is associated with improved progression-free and overall survival in patients undergoing autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma (DLBCL) [abstract]. Blood 2007, 110: Abstract 19.
33. Gisselbrecht C, Schmitz N, Mounier N, et al.: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: First interim analysis on 200 patients. CORAL study [abstract 517]. Blood 2007, 110: 159a.
34. Friedberg JW, Neuberg D, Stone RM, et al.: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3135.
35. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al.: Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999, 106: 1020-1026.
36. Press OW, Eary JF, Appelbaum FR, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329: 1219-1224.
37. Gopal AK, Rajendran JG, Gooley TA, et al.: High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007, 25: 1396-1402.
38. Liu SY, Eary JF, Petersdorf SH, et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16: 3270-3278.
39. Vose JM, Bierman PJ, Enke C, et al.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005, 23: 461-467.
40. Vose J, Bierman PJ, Bociek G, et al.: Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation [ASCO abstract 8013]. J Clin Oncol 2007, 25(18S): 8013.
41. Krishnan A, Nademanee A, Fung HC, et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008, 26: 90-95.
42. Nademanee A, Forman S, Molina A, et al.: A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005, 106: 2896-2902.
43. Shimoni A, Zwas ST, Oksman Y, et al.: Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007, 35: 534-540.
44. Winter JN, Inwards DJ, Spies S, et al.: 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL [abstract 330]. Blood 2006, 108: 127.
45. Alousi AM, Hosing C, Saliba R, et al.: Zevalin/BEAM/rituximab vs BEAM/ rituximab and autologous stem cell transplantation (ASCT) for relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL): Impact of the IPI and PET status [abstract]. Blood 2007, 110: 620.
46. Vose JM, Bierman PJ, Anderson JR, et al.: Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood 1992, 80: 2142-2148.
47. Kewalramani T, Nimer SD, Zelenetz AD, et al.: Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003, 32: 673-679.
48. Pott C, Schrader C, Gesk S, et al.: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107: 2271-2278.
49. Khouri IF, Saliba RM, Hosing C, et al.: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005, 23: 2240-2247.
50. Horwitz SM, Negrin RS, Blume KG, et al.: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004, 103: 777-783.
51. Shimoni A, Hardan I, Avigdor A, et al.: Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003, 122: 457-464.
52. Lee MY, Chiou TJ, Hsiao LT, et al.: Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008, 87: 285-289.
53. Lemieux B, Tartas S, Traulle C, et al.: Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33: 921-923.
54. Shortt J, Spencer A: Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006, 38: 433-436.
55. Borrello I, Sotomayor EM, Rattis FM, et al.: Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000, 95: 3011-3019.
56. Kline J, Subbiah S, Lazarus HM, van Besien K: Autologous graft-versus-host disease: Harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant 2008, 41: 505-513.
57. Thompson JA, Fisher RI, Leblanc M, et al.: Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: Results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008, 111: 4048-4054.
58. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31: 667-678.
59. van Besien KW, de Lima M, Giralt SA, et al.: Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997, 19: 977-982.
60. Dhedin N, Giraudier S, Gaulard P, et al.: Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Societe Francaise de Greffe de Moelle. Br J Haematol 1999, 107: 154-161.
61. Doocey RT, Toze CL, Connors JM, et al.: Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005, 131: 223-230.
62. Rodriguez R, Nademanee A, Ruel N, et al.: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12: 1326-1334.
63. Faulkner RD, Craddock C, Byrne JL, et al.: BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103: 428-434.
64. Morris E, Thomson K, Craddock C, et al.: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104: 3865-3871.
65. Robinson SP, Goldstone AH, Mackinnon S, et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100: 4310-4316.
66. Freytes CO, Loberiza FR, Rizzo JD, et al.: Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood 2004, 104: 3797-3803.
67. Escalon MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation: A promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004, 22: 2419-2423.
68. Branson K, Chopra R, Kottaridis PD, et al.: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20: 4022-4031.
69. Baron F, Storb R, Storer BE, et al.: Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006, 24: 4150-4157.
70. El Gnaoui T, Dupuis J, Belhadj K, et al.: Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007, 18: 1363-1368.
71. Lopez A, Gutierrez A, Palacios A, et al.: GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study. Eur J Haematol 2008, 80: 127-132.
72. Morschhauser F, Illidge T, Huglo D, et al.: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007, 110: 54-58.
73. Press OW, Eary JF, Gooley T, et al.: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000, 96: 2934-2942.
74. Gopal AK, Pagel JM, Rajendran JG, et al.: Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant 2006, 12: 697-702.